NCI Cancer Biomarkers Consortium
GPTKB entity
Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:political_organization
|
| gptkbp:addresses |
cancer heterogeneity
|
| gptkbp:aims_to |
improve patient outcomes
accelerate biomarker discovery |
| gptkbp:collaborates_with |
academic institutions
pharmaceutical companies |
| gptkbp:conducts |
workshops
|
| gptkbp:develops |
biomarker assays
|
| gptkbp:engages_in |
data sharing
|
| gptkbp:established_in |
gptkb:2004
|
| gptkbp:facilitates |
collaborative research
|
| gptkbp:focuses_on |
cancer biomarkers
|
| gptkbp:has_collaborations_with |
international organizations
|
| gptkbp:has_goal |
foster innovation
increase collaboration enhance biomarker validation reduce time to market for biomarkers |
| gptkbp:has_impact_on |
patient care
cancer research clinical practice |
| gptkbp:has_members |
gptkb:researchers
industry partners clinicians |
| https://www.w3.org/2000/01/rdf-schema#label |
NCI Cancer Biomarkers Consortium
|
| gptkbp:is_active_in |
gptkb:2004
|
| gptkbp:is_funded_by |
gptkb:National_Institutes_of_Health
|
| gptkbp:is_involved_in |
clinical research
translational research regulatory science biomarker development projects biomarker discovery initiatives biomarker validation studies |
| gptkbp:is_located_in |
gptkb:United_States
|
| gptkbp:is_recognized_by |
gptkb:scientific_community
industry stakeholders regulatory agencies |
| gptkbp:is_supported_by |
government funding
private funding |
| gptkbp:part_of |
gptkb:National_Institutes_of_Health
|
| gptkbp:promotes |
standardization of biomarkers
|
| gptkbp:provides |
resources for research
|
| gptkbp:provides_access_to |
clinical data
biomarker data |
| gptkbp:publishes |
research findings
|
| gptkbp:supports |
clinical trials
|
| gptkbp:utilizes |
biological samples
|
| gptkbp:works_on |
treatment response
early detection of cancer prognostic markers predictive markers |
| gptkbp:bfsParent |
gptkb:National_Cancer_Institute's_Office_of_Cancer_Biomarkers
|
| gptkbp:bfsLayer |
4
|